Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection (ELACOI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04252885
Recruitment Status : Completed
First Posted : February 5, 2020
Last Update Posted : July 1, 2020
Sponsor:
Information provided by (Responsible Party):
Linghua LI, Guangzhou 8th People's Hospital

Brief Summary:
The study explores the efficacy of lopinavir plus ritonavir and arbidol in treating with novel coronavirus infection. As a result this study would provide evidence for the clinical usage of these drugs in the future .

Condition or disease Intervention/treatment Phase
Coronavirus Infections Drug: Lopinavir and Ritonavir Tablets Drug: Arbidol Phase 4

Detailed Description:
This is a phase IV, open-labelled, randomized controlled clinical trial. A total of 125 cases who are novel coronavirus positive are planned to be recruited. These cases are randomized into 3 groups: in group A(Standard treatment+lopinavir/ritonavir), 50 cases are given ordinary treatment plus a regimen of lopinavir (200mg) and ritonavir (50mg) (oral, q12h, every time 2 tablets of each, taking for 7-14 days). In group B(Standard treatment+arbidol) , 50 cases are given ordinary treatment plus a regimen of arbidol (100mg) (oral, tid, 200mg each time, taking for 7-14 days). In group C(Standard treatment), 25 cases are only given ordinary treatment. The observation duration is 21 days. Patients will be followed up at baseline (day 0) and day 2, 4, 7, 10,14, 21 after receiving indicated treatment. The primary observed indicators include viral nucleic in acid nose / throat swab, body temperature, respiratory rate, oxygen saturation of blood, chest imaging. The secondary observed indicators include but not limited to blood pressure, heart rate, blood routine test, liver and kidney function, myocardial enzyme, flow cytometry classification and counting, cytokines, other infection indicators, conditions and parameters of auxiliary respiration, the total days in hospital, exacerbation and mortality.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 86 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 125 patients are randomized in 3 groups (2:2:1). In group A(Standard treatment+lopinavir/ritonavir) , 50 cases are given ordinary treatment plus a regimen of lopinavir (200mg) and ritonavir (50mg) (oral, q12h, every time 2 tablets of each, taking for 7-14 days). In group B (Standard treatment+arbidol), 50 cases are given ordinary treatment plus a regimen of arbidol (100mg) (oral, tid, 200mg each time, taking for 7-14 days). In group C (Standard treatment), 25 cases are only given ordinary treatment.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection
Actual Study Start Date : January 28, 2020
Actual Primary Completion Date : April 30, 2020
Actual Study Completion Date : May 31, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group A-Standard treatment+lopinavir/ritonavir
In group A, 50 cases are given ordinary treatment plus a regimen of lopinavir (200mg) and ritonavir (50mg) (oral, q12h, every time 2 tablets of each, taking for 7-14 days).
Drug: Lopinavir and Ritonavir Tablets
As indicated in arm/group descriptions
Other Name: Kletra

Active Comparator: Group B-Standard treatment+arbidol
In group B, 50 cases are given ordinary treatment plus a regimen of arbidol (100mg) (oral, tid, 200mg each time, taking for 7-14 days).
Drug: Arbidol
As indicated in arm/group descriptions

No Intervention: Group C-Standard treatment
In group C, 25 cases are only given ordinary treatment.



Primary Outcome Measures :
  1. The rate of virus inhibition [ Time Frame: Day 0, 2, 4, 7, 10, 14 and 21 ]
    Novel coronaviral nucleic acid is measured in nose / throat swab at each time point.


Secondary Outcome Measures :
  1. The disease prorogation-temperature [ Time Frame: Day 0 till day 21 ]
    Body temperature will be followed everyday during time frame.

  2. The disease prorogation-respiratory function 1 [ Time Frame: Day 0 till day 21 ]
    Respiratory rate will be followed everyday during time frame.

  3. The disease prorogation-respiratory function 2 [ Time Frame: Day 0 till day 21 ]
    Oxygen saturation of blood will be followed everyday during time frame.

  4. The disease prorogation-respiratory function 3 [ Time Frame: Day 0, 4, 7, 10, 14 and 21 ]
    Chest imaging will be taken at each time point.


Other Outcome Measures:
  1. Patients health condition-routine test [ Time Frame: Day 0 till day 21 ]
    Blood pressure and heart rate will be followed everyday during time frame.

  2. Patients health condition-liver function [ Time Frame: Day 0, 4, 7, 10, 14 and 21 ]
    Liver function will be assessed as AST, ALT and TBIL at each time point.

  3. Patients health condition-kidney function [ Time Frame: Day 0, 4, 7, 10, 14 and 21 ]
    Kidney function will be assessed as eGFR and creatine clearance rate at each time point.

  4. Patients health condition-other blood routine test [ Time Frame: Day 0, 4, 7, 10, 14 and 21 ]
    Blood routine and myocardial enzyme will be measured at each time point.

  5. Patients health condition-blood routine test [ Time Frame: Day 0, 4, 7, 10, 14 and 21 ]
    Flow cytometry classification and counting and cytokines will be measured at each time point.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • In sputum, throat swab, lower respiratory tract secretion, blood and other samples, the nucleic acid of the novel coronavirus was positive, or the sequencing of the virus gene was highly homologous with the known novel coronavirus
  • Age is between 18-80 years old, the weight is more than 30kg, and there is no limit for men and women
  • The following conditions were met: creatinine ≤ 110 umol / L, creatinine clearance rate (EGFR) ≥ 60 ml / min / 1.73m2, AST and ALT ≤ 5 × ULN, TBIL ≤ 2 × ULN;
  • The subjects should fully understand the purpose, nature, method and possible reaction of the study, voluntarily participate in the study and sign the informed consent.

Exclusion Criteria:

  • Have a clear history of lopinavir or ritonavir or arbidol allergy
  • Severe nausea, vomiting, diarrhea and other clinical manifestations affect the oral or absorption of the drugs
  • At the same time, take drugs that may interact with lopinavir or ritonavir or arbidol
  • Patients with serious underlying diseases, including but not limited to heart disease (including history of angina pectoris or coronary heart disease or myocardial infarction, atrioventricular block), lung, kidney, liver malfunction and mental diseases that cannot be treated together
  • ancreatitis or hemophilia
  • Pregnant and lactating women
  • Suspected or confirmed history of alcohol and drug abuse
  • Participated in other drug trials in the past month
  • The researchers judged that patients were not suitable for the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04252885


Locations
Layout table for location information
China, Guangdong
Guangzhou Eighth People's Hospital
Guangzhou, Guangdong, China, 510060
Sponsors and Collaborators
Guangzhou 8th People's Hospital
Layout table for additonal information
Responsible Party: Linghua LI, Vice chief of Infectious Disease Center, Guangzhou 8th People's Hospital
ClinicalTrials.gov Identifier: NCT04252885    
Other Study ID Numbers: GZ8H-V1.0 20200122
First Posted: February 5, 2020    Key Record Dates
Last Update Posted: July 1, 2020
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Linghua LI, Guangzhou 8th People's Hospital:
Coronavirus infection
Lopinarvir plus ritonavir
Arbidol
Efficacy
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Coronavirus Infections
Severe Acute Respiratory Syndrome
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Ritonavir
Lopinavir
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors